Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Jiang Wenbin, holds the title of PRESIDENT AND CEO at Cytek Biosciences, Inc..
On 2026-11-18, the insider transacted 167,354 shares.The shares were transacted at a weighted average price of $1.67 per share, resulting in a total market-relevant value of $280K.
Jiang Wenbin (PRESIDENT AND CEO) had withheld for taxes $280K of $CTKB
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.